This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (402)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Laurel J. Steinherz, MD; Peter G. Steinherz, MD; Charlotte T. C. Tan, MD; Glenn Heller, PhD; M. Lois Murphy, MD

JAMA. 1991;266(12):1672-1677.

Abstract
Objective.
—To assess the cardiac status of long-term survivors of pediatric malignancies who received chemotherapy, including anthracyclines.

Design and Method.
—Patients were evaluated by echocardiogram from 4 to 20 years (median, 7 years) after completion of anthracyclines, with prospective and retrospective analysis.

Patients.
—The consecutive sample of 201 patients had received a total anthracycline dose of 200 to 1275 mg/m² (median, 450 mg/m2), and 51 patients had mediastinal radiotherapy.

Main Outcome Measures.
—The overall incidence and severity of abnormal systolic cardiac function were determined for the entire cohort. Risk factors of total anthracycline dose, mediastinal radiotherapy, age during treatment, and length of follow-up were examined.

Results.
—Twenty-three percent (47/201) of the cohort had abnormal cardiac function on noninvasive testing at long-term follow-up. Correlation between total cumulative dose, length of follow-up, and mediastinal irradiation with incidence of abnormalities was significant. Fifty-six patients were followed up for 10 years or more (median, 12 years), with a median anthracycline dose of 495 mg/m², Thirty-eight percent (21/56) of these patients, compared with 18% (26/145) of patients evaluated after less than 10 years, had abnormal findings. Sixty-three percent of patients followed up for 10 years or more after receiving 500 mg/m² or more of anthracyclines had abnormal findings. Nine of 201 patients had late symptoms, including cardiac failure and dysrhythmia, and three patients died suddenly. Microscopic examination of the myocardium on biopsy and autopsy revealed fibrosis.

Conclusion.
—The 23% incidence of late cardiac abnormalities warrants continued evaluation of patients after anthracyclines to guide patient care and the design of future chemotherapeutic protocols.

(JAMA. 1991;266:1672-1677)

Author Affiliations
From the Department of Pediatrics (Drs L. J. Steinherz, P. G. Steinherz, Tan, and Murphy) and the Department of Epidemiology and Biostatistics (Dr Heller), Memorial Sloan-Kettering Cancer Center, New York, NY.

Footnotes
Reprints requests to Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021 (Dr L. J. Steinherz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Role of Anthracyclines in the Treatment of Early Breast Cancer
Gianni et al.
JCO 2009;27:4798-4808.
ABSTRACT | FULL TEXT  

Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity
Zhang et al.
Am. J. Physiol. Heart Circ. Physiol. 2009;297:H37-H46.
ABSTRACT | FULL TEXT  

A Review of the Cardiovascular Effects of Oncology Agents
Frei and Soefje
Journal of Pharmacy Practice 2008;21:146-158.
ABSTRACT  

Strength Training by Children and Adolescents
Council on Sports Medicine and Fitness
Pediatrics 2008;121:835-840.
ABSTRACT | FULL TEXT  

Medical Conditions Affecting Sports Participation
Rice and and the Council on Sports Medicine and Fitness
Pediatrics 2008;121:841-848.
ABSTRACT | FULL TEXT  

Early Breast Cancer Therapy and Cardiovascular Injury
Steinherz
J Am Coll Cardiol 2008;51:1235-1235.
FULL TEXT  

Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group
Shankar et al.
Pediatrics 2008;121:e387-e396.
ABSTRACT | FULL TEXT  

Monitoring of Anthracycline-Induced Cardiotoxicity
Jannazzo et al.
The Annals of Pharmacotherapy 2008;42:99-104.
ABSTRACT | FULL TEXT  

Anthracycline-induced Cardiotoxicity: Natural History, Risk Factors, and Prevention
Barry et al.
Am Soc Clin Oncol Ed Book 2008;2008:448-453.
ABSTRACT | FULL TEXT  

In Reply
Telli et al.
JCO 2007;25:5533-5534.
FULL TEXT  

Effects of Dexrazoxane and Amifostine on Evolution of Doxorubicin Cardiomyopathy In Vivo
Bjelogrlic et al.
Exp. Biol. Med. 2007;232:1414-1424.
ABSTRACT | FULL TEXT  

Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity
Deng et al.
Eur J Heart Fail 2007;9:986-994.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
Carver et al.
JCO 2007;25:3991-4008.
ABSTRACT | FULL TEXT  

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer
Pinder et al.
JCO 2007;25:3808-3815.
ABSTRACT | FULL TEXT  

Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors
Hudson et al.
JCO 2007;25:3635-3643.
ABSTRACT | FULL TEXT  

An Affair of the Heart
Boice
JNCI J Natl Cancer Inst 2007;99:186-187.
FULL TEXT  

Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics
Kavey et al.
Circulation 2006;114:2710-2738.
ABSTRACT | FULL TEXT  

Doxorubicin in experimental and clinical heart failure.
Christiansen and Autschbach
Eur. J. Cardiothorac. Surg. 2006;30:611-616.
ABSTRACT | FULL TEXT  

Long-term cardiac follow-up in survivors of a malignant bone tumour
Brouwer et al.
Ann Oncol 2006;17:1586-1591.
ABSTRACT | FULL TEXT  

Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury
Neilan et al.
Eur Heart J 2006;27:1868-1875.
ABSTRACT | FULL TEXT  

Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin
Li et al.
Circulation 2006;113:2211-2220.
ABSTRACT | FULL TEXT  

Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression
Neilan et al.
Eur Heart J 2006;27:1251-1256.
ABSTRACT | FULL TEXT  

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
Moser et al.
Blood 2006;107:2912-2919.
ABSTRACT | FULL TEXT  

Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study
Tassan-Mangina et al.
Eur J Echocardiogr 2006;7:141-146.
ABSTRACT | FULL TEXT  

Exercise capacity in apparently healthy survivors of cancer
De Caro et al.
Arch. Dis. Child. 2006;91:47-51.
ABSTRACT | FULL TEXT  

NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity
Wojnowski et al.
Circulation 2005;112:3754-3762.
ABSTRACT | FULL TEXT  

Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
Doyle et al.
JCO 2005;23:8597-8605.
ABSTRACT | FULL TEXT  

N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?
Sandri et al.
Clin. Chem. 2005;51:1405-1410.
ABSTRACT | FULL TEXT  

Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity
Conklin
Integr Cancer Ther 2005;4:110-130.
ABSTRACT  

Using Health-Related Quality of Life Measures to Predict Cardiac Function in Survivors Exposed to Anthracyclines
Ginsberg et al.
JCO 2004;22:3149-3155.
ABSTRACT | FULL TEXT  

Reversible Ageusia after Chemotherapy with Pegylated Liposomal Doxorubicin
Kiewe et al.
The Annals of Pharmacotherapy 2004;38:1212-1214.
ABSTRACT | FULL TEXT  

Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
Cardinale et al.
Circulation 2004;109:2749-2754.
ABSTRACT | FULL TEXT  

Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Minotti et al.
Pharmacol. Rev. 2004;56:185-229.
ABSTRACT | FULL TEXT  

Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
Hequet et al.
JCO 2004;22:1864-1871.
ABSTRACT | FULL TEXT  

Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to Anthracyclines
Silber et al.
JCO 2004;22:820-828.
ABSTRACT | FULL TEXT  

Repetitive Dobutamine Stress Echocardiography for the Prediction of Anthracycline Cardiotoxicity
Bountioukos et al.
Eur J Echocardiogr 2003;4:300-305.
ABSTRACT | FULL TEXT  

Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin's Disease
Aleman et al.
JCO 2003;21:3431-3439.
ABSTRACT | FULL TEXT  

Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists
Navari and Koeller
The Annals of Pharmacotherapy 2003;37:1276-1286.
ABSTRACT | FULL TEXT  

Long-Term Prospective Follow-Up Study of Cardiac Function After Cardiotoxic Therapy for Malignancy in Children
Poutanen et al.
JCO 2003;21:2349-2356.
ABSTRACT | FULL TEXT  

Sinus Tachyarrhythmias and the Specific Bradycardic Agents: A Marriage Made in Heaven?
Yusuf and Camm
J CARDIOVASC PHARMACOL THER 2003;8:89-105.
ABSTRACT  

Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase
Duquaine et al.
Vasc Med 2003;8:101-107.
ABSTRACT  

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma
Limat et al.
Ann Oncol 2003;14:277-281.
ABSTRACT | FULL TEXT  

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up
Avvisati et al.
Blood 2002;100:3141-3146.
ABSTRACT | FULL TEXT  

The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage
Goethals et al.
Ann Oncol 2002;13:1331-1339.
ABSTRACT | FULL TEXT  

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review
Kremer et al.
Ann Oncol 2002;13:819-829.
ABSTRACT | FULL TEXT  

Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis
Gharib and Burnett
Eur J Heart Fail 2002;4:235-242.
ABSTRACT | FULL TEXT  

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
Jensen et al.
Ann Oncol 2002;13:699-709.
ABSTRACT | FULL TEXT  

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale et al.
Ann Oncol 2002;13:710-715.
ABSTRACT | FULL TEXT  

The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern?
Keefe
The Oncologist 2002;7:65-72.
ABSTRACT | FULL TEXT  

Late Mortality Experience in Five-Year Survivors of Childhood and Adolescent Cancer: The Childhood Cancer Survivor Study
Mertens et al.
JCO 2001;19:3163-3172.
ABSTRACT | FULL TEXT  

Prospective Evaluation of Early Cardiac Damage Induced by Epirubicin-Containing Adjuvant Chemotherapy and Locoregional Radiotherapy in Breast Cancer Patients
Meinardi et al.
JCO 2001;19:2746-2753.
ABSTRACT | FULL TEXT  

Congestive Heart Failure After Treatment for Wilms' Tumor: A Report From the National Wilms' Tumor Study Group
Green et al.
JCO 2001;19:1926-1934.
ABSTRACT | FULL TEXT  

Attenuation of Doxorubicin Chronic Toxicity in Metallothionein-overexpressing Transgenic Mouse Heart
Sun et al.
Cancer Res. 2001;61:3382-3387.
ABSTRACT | FULL TEXT  

Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation
Zambetti et al.
JCO 2001;19:37-43.
ABSTRACT | FULL TEXT  

Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study
Kremer et al.
JCO 2001;19:191-196.
ABSTRACT | FULL TEXT  

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale et al.
J Am Coll Cardiol 2000;36:517-522.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants
Hensley et al.
JCO 1999;17:3333-3355.
ABSTRACT | FULL TEXT  

Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes
Working et al.
J. Pharmacol. Exp. Ther. 1999;289:1128-1133.
ABSTRACT | FULL TEXT  

Management options: Anthracycline-induced cardiomyopathy
Fisher and Marshall
Postgrad. Med. J. 1999;75:265-268.
ABSTRACT | FULL TEXT  

Drug-induced heart failure
Feenstra et al.
J Am Coll Cardiol 1999;33:1152-1162.
ABSTRACT | FULL TEXT  

Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables
Tjeerdsma et al.
Heart 1999;81:419-423.
ABSTRACT | FULL TEXT  

Long-Term Survivors of Childhood Cancer: The Late Effects of Therapy
Schwartz
The Oncologist 1999;4:45-54.
ABSTRACT | FULL TEXT  

Mantle Irradiation Alone for Clinical Stage I-II Hodgkin's Disease: Long-Term Follow-Up and Analysis of Prognostic Factors in 261 Patients
Wirth et al.
JCO 1999;17:230-230.
ABSTRACT | FULL TEXT  

Doxorubicin-Induced Cardiomyopathy
Singal and Iliskovic
NEJM 1998;339:900-905.
FULL TEXT  

Late Effects in Survivors of Bone Tumors Late Effects in Survivors of Bone Tumors
Mosher and McCarthy
Journal of Pediatric Oncology Nursing 1998;15:72-84.
ABSTRACT  

Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer
Lipshultz et al.
NEJM 1995;332:1738-1744.
ABSTRACT | FULL TEXT  

Probucol Protects Against Adriamycin Cardiomyopathy Without Interfering With Its Antitumor Effect
Siveski-Iliskovic et al.
Circulation 1995;91:10-15.
ABSTRACT | FULL TEXT  

Doxorubicin-Induced Cardiomyopathy
Dunn
Journal of Pediatric Oncology Nursing 1994;11:152-160.
ABSTRACT  

LATE CARDIAC TOXICITY FROM ANTHRACYCLINE THERAPY
JWatch General 1991;1991:4-4.
FULL TEXT